Delivering on our research strategy: New Research Advisory Group (RAG) shapes future research

In April, Myeloma UK launched our landmark research strategy. Our strategy is driven by people affected by myeloma and associated conditions as well as the amazing myeloma research leaders and clinicians who support them. Our goal is to accelerate research in preventing, treating and living well with myeloma, and find new ways to a cure.

Diversifying and further strengthening the Research Advisory Group

Myeloma UK has always been a close partner of the clinical community, holding a unique place in the research landscape. One of our early aims was to build on this partnership, strengthening and diversifying the RAG to ensure our research is built on the best of international science and medicine and informed by people with lived experience. We know that by working together in this way we can ensure that we fund and promote research that puts patients first.  

Following a successful recruitment drive in May 2025, the RAG has increased from six to 13 members and is now comprised of a mixture of haematologists (with a focus on myeloma), basic scientists, allied healthcare professionals, statisticians and people with lived experience. Each member brings their unique expertise and perspective on what will deliver the biggest impact in research, for people living with myeloma.  

Incorporating a more diverse range of skills, experiences, geographical locations and backgrounds ensures that the RAG truly reflects the voices of those affected by myeloma.  

Refreshed RAG at work: Horizon scanning 2025

We’ve committed to annual awards of multi-year research funding in our research strategy. The first meeting of the newly formed RAG took place in July and focused on looking at the current myeloma research landscape to identify research topics for investment that will help improve the lives of those affected by myeloma. 

Workshops, led by Professor Gordon Cook (RAG Chair) and Professor Graham Jackson (Myeloma UK Chief Clinical & Scientific Advisor), allowed the RAG to explore potential areas of research most likely to impact patient lives. It was fantastic to see all our members contribute to the discussions, especially those with lived experience, as their voice is critical for us to succeed in achieving our research aims.

Building upon the research strategy, the conversations culminated in recommendations for research topics – these will now go to the Myeloma UK Research, Clinical & Access (RCA) Committee, and, subject to approval, will form the 2026 grant call.

Upholding the six principles of expert review 

As a member of the Association of Medical Research Charities (AMRC), we’re committed to ensuring our funding decisions are guided by the six principles of expert review: proportionality, independence, diversity, rotation, impartiality and transparency. The expert review (also known as peer review), carried out by independent experts with relevant knowledge or experience in a particular subject area, assesses the quality, originality and validity of research applications.  

Following the six principles ensures not only that Myeloma UK supports the highest quality research, but that it also has maximum impact and can deliver benefit in a robust and rigorous way. 

A key development of the RAG is the inclusion of people who live with myeloma – people who are experts by experience. This brings crucial insight and perspective to our decisions and helps to shape the future of our research in ways that truly reflect the priorities of those affected by myeloma. 

We at Myeloma UK would like to extend our gratitude to the RAG for their invaluable input in shaping our next grant call. By listening to a diverse range of voices, we can turn our research strategy into reality and make a significant difference to those affected by myeloma.